ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.
By S. Vesely, J. George, B. Lämmle, J. Studt, L. Alberio, Mayez A. El-Harake, G. Raskob. Blood, 2003
711 citations recorded by the source corpus.
Subfields: Hematology, Immunology, Nephrology
View Paper: https://www.semanticscholar.org/paper/8d874ebb9e7368edec6974c69faad2a1c369eb58
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Immunology
In Nephrology
Citations in the corpus
- FRETS‐VWF73, a first fluorogenic substrate for ADAMTS13 assay (2005, background): “…ADAMTS13 deficiency is observed in most patients with idiopathic TTP without pre-existing medical conditions (Furlan et al, 1998; Tsai & Lian, 1998), the association between ADAMTS13 deficiency and TTP is unclear in less highly selected patient groups (Veyradier et al, 2001; Vesely et al, 2003).”